The Diabetic Boot Company, Trading as PulseFlow Technologies, has developed PulseFlowDF®, a new class2 medical device, which combines diabetic friendly footwear, integrated offloading capabilities and patented Pulseflow technology which aids in the promotion of blood flow and improved tissue oxygenation in one product. In the UK £650m a year is spent on diabetic foot ulcer treatment and subsequent amputations, however, many such disabling surgeries are avoidable given proper care and special diabetic footwear. Improving foot care and reducing the number of diabetic foot ulcers and amputations are key aims for health systems around the globe.

FDA cleared, CE marked & patented $1billion opportunity, supported by Global Experts in the field

De-risked investment opportunity; clear business model

Diabetes is growing exponentially; so are diabetic foot ulcers (DFU). Costly (~$32,000) to heal, leading to amputation in 20% of cases.

PulseFlowDF addresses 4 needs of these hard to heal wounds

  • Looks like normal footwear (social stigma)
  • Records patient compliance (improves healing)
  • Pumps blood round the foot (improves oxygenation)
  • Reduces pressure on wound during walking (faster healing)